Defective activation of the pyruvate dehydrogenase complex in subacute necrotizing encephalomyelopathy (Leigh disease).
Autopsy examination confirmed the diagnosis of subacute necrotizing encephalomyelopathy (SNE) in a 7-month-old male infant who underwent several metabolic studies before death. Intermittent lactic acidemia and fumaric aciduria, an extreme hyperglycemic response to an intravenous bolus of alanine, and an elevated total body flux rate of glucose (58.4 mumoles . kg-1 . min-1) suggested a disturbance in the oxidative decarboxylation of pyruvate. Enzymological studies of postmortem samples revealed low nonactivated pyruvate dehydrogenase activity in liver (19.4%) and brain (53.8%). The lowest brain pyruvate dehydrogenase activities were noted in the midbrain and pontine regions. Supramaximal activation of the hepatic pyruvate dehydrogenase complex (135% of control values) occurred in vitro. Spontaneous reactivation following in vitro inactivation of the complex with adenosine triphosphate was significantly less (p less than 0.02) in the patient's samples compared to controls. The biochemical defect was not apparent in fibroblasts. These enzymological observations point to an in vivo defect in the activation mechanism of the pyruvate dehydrogenase complex as the biochemical disturbance in SNE. The findings suggest that dichloroacetate may be beneficial in treating SNE.
D000409:Alanine; D001786:Blood Glucose / Q000378:metabolism; D001921:Brain / Q000201:enzymology* / Q000473:pathology; D001927:Brain Diseases / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D003653:Decarboxylation; D003999:Dichloroacetic Acid / Q000627:therapeutic use; D004789:Enzyme Activation; D005347:Fibroblasts / Q000201:enzymology; D006801:Humans; D066298:In Vitro Techniques; D007223:Infant; D008099:Liver / Q000201:enzymology*; D009336:Necrosis; D010766:Phosphorylation; D015325:Pyruvate Dehydrogenase Complex Deficiency Disease; D013577:Syndrome
D001786:Blood Glucose; D003999:Dichloroacetic Acid; D000409:Alanine